Shares of Cogent Biosciences, Inc. (NASDAQ: COGT) surged 4.14% in pre-market trading on Tuesday, July 15, 2025, reaching $11.55. This rise comes after the stock closed at $11.09 in the previous session.
The boost follows the announcement of positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial for bezuclastinib in patients with non-advanced systemic mastocytosis. The trial showed clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden.
